These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 16022863)

  • 1. A role for endocannabinoids in viral-induced dyskinetic and convulsive phenomena.
    Solbrig MV; Adrian R; Baratta J; Piomelli D; Giuffrida A
    Exp Neurol; 2005 Aug; 194(2):355-62. PubMed ID: 16022863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.
    Cabranes A; Venderova K; de Lago E; Fezza F; Sánchez A; Mestre L; Valenti M; García-Merino A; Ramos JA; Di Marzo V; Fernández-Ruiz J
    Neurobiol Dis; 2005 Nov; 20(2):207-17. PubMed ID: 16242629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of subthalamic neuron activity by endocannabinoids.
    Morera-Herreras T; Ruiz-Ortega JA; Taupignon A; Baufreton J; Manuel I; Rodriguez-Puertas R; Ugedo L
    Synapse; 2010 Sep; 64(9):682-98. PubMed ID: 20336631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anxiolytic-like properties of the anandamide transport inhibitor AM404.
    Bortolato M; Campolongo P; Mangieri RA; Scattoni ML; Frau R; Trezza V; La Rana G; Russo R; Calignano A; Gessa GL; Cuomo V; Piomelli D
    Neuropsychopharmacology; 2006 Dec; 31(12):2652-9. PubMed ID: 16541083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity.
    Wallace MJ; Martin BR; DeLorenzo RJ
    Eur J Pharmacol; 2002 Oct; 452(3):295-301. PubMed ID: 12359270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models.
    Mitchell VA; Greenwood R; Jayamanne A; Vaughan CW
    Clin Exp Pharmacol Physiol; 2007 Nov; 34(11):1186-90. PubMed ID: 17880375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anandamide attenuates haloperidol-induced vacuous chewing movements in rats.
    Röpke J; Busanello A; Leal CQ; de Moraes Reis E; de Freitas CM; Villarinho JG; Figueira FH; Mello CF; Ferreira J; Fachinetto R
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Oct; 54():195-9. PubMed ID: 24747871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta.
    Herradón E; Martín MI; López-Miranda V
    Br J Pharmacol; 2007 Nov; 152(5):699-708. PubMed ID: 17704831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocannabinoids mediate anxiolytic-like effect of acetaminophen via CB1 receptors.
    Umathe SN; Manna SS; Utturwar KS; Jain NS
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Oct; 33(7):1191-9. PubMed ID: 19580839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential role of the hippocampal endocannabinoid system in the memory consolidation and retrieval mechanisms.
    De Oliveira Alvares L; Genro BP; Diehl F; Quillfeldt JA
    Neurobiol Learn Mem; 2008 Jul; 90(1):1-9. PubMed ID: 18342551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CB1 agonists, locally applied to the cortico-thalamic circuit of rats with genetic absence epilepsy, reduce epileptic manifestations.
    Citraro R; Russo E; Ngomba RT; Nicoletti F; Scicchitano F; Whalley BJ; Calignano A; De Sarro G
    Epilepsy Res; 2013 Sep; 106(1-2):74-82. PubMed ID: 23860329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticonvulsive effects of endocannabinoids; an investigation to determine the role of regulatory components of endocannabinoid metabolism in the Pentylenetetrazol induced tonic- clonic seizures.
    Zareie P; Sadegh M; Palizvan MR; Moradi-Chameh H
    Metab Brain Dis; 2018 Jun; 33(3):939-948. PubMed ID: 29504066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias.
    Ferrer B; Asbrock N; Kathuria S; Piomelli D; Giuffrida A
    Eur J Neurosci; 2003 Sep; 18(6):1607-14. PubMed ID: 14511339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabinoid receptor activation disrupts the internal structure of hippocampal sharp wave-ripple complexes.
    Sun Y; Norimoto H; Pu XP; Matsuki N; Ikegaya Y
    J Pharmacol Sci; 2012; 118(2):288-94. PubMed ID: 22293299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attenuation of kainic acid-induced status epilepticus by inhibition of endocannabinoid transport and degradation in guinea pigs.
    Shubina L; Aliev R; Kitchigina V
    Epilepsy Res; 2015 Mar; 111():33-44. PubMed ID: 25769371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The endocannabinoid transport inhibitor AM404 modulates nociception in cholestasis.
    Hasanein P
    Neurosci Lett; 2009 Oct; 462(3):230-4. PubMed ID: 19616063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease.
    van der Stelt M; Fox SH; Hill M; Crossman AR; Petrosino S; Di Marzo V; Brotchie JM
    FASEB J; 2005 Jul; 19(9):1140-2. PubMed ID: 15894565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-Arachidonylglycerol acting on CB1 cannabinoid receptors mediates delayed cardioprotection induced by nitric oxide in rat isolated hearts.
    Wagner JA; Abesser M; Harvey-White J; Ertl G
    J Cardiovasc Pharmacol; 2006 May; 47(5):650-5. PubMed ID: 16775503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of endocannabinoids on [(3)H]-GABA uptake in the rat globus pallidus.
    Venderova K; Brown TM; Brotchie JM
    Exp Neurol; 2005 Jul; 194(1):284-7. PubMed ID: 15899265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications.
    Tzavara ET; Li DL; Moutsimilli L; Bisogno T; Di Marzo V; Phebus LA; Nomikos GG; Giros B
    Biol Psychiatry; 2006 Mar; 59(6):508-15. PubMed ID: 16199010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.